Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB - Asset Resilience Ratio
Isofol Medical AB (ISOFOL) has an Asset Resilience Ratio of 65.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Isofol Medical AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Isofol Medical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr85.00 Million | 65.69% |
| Total Liquid Assets | Skr85.00 Million | 65.69% |
Asset Resilience Insights
- Very High Liquidity: Isofol Medical AB maintains exceptional liquid asset reserves at 65.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Isofol Medical AB Industry Peers by Asset Resilience Ratio
Compare Isofol Medical AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Isofol Medical AB (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Isofol Medical AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.69% | Skr85.00 Million | Skr129.40 Million | -32.01pp |
| 2024-12-31 | 97.70% | Skr96.16 Million | Skr98.42 Million | -0.55pp |
| 2023-12-31 | 98.26% | Skr138.15 Million | Skr140.60 Million | +8.98pp |
| 2022-12-31 | 89.28% | Skr190.58 Million | Skr213.46 Million | -5.26pp |
| 2021-12-31 | 94.54% | Skr379.45 Million | Skr401.36 Million | +15.96pp |
| 2020-12-31 | 78.57% | Skr116.39 Million | Skr148.13 Million | -8.12pp |
| 2019-12-31 | 86.70% | Skr126.98 Million | Skr146.47 Million | -7.88pp |
| 2018-12-31 | 94.57% | Skr272.90 Million | Skr288.55 Million | -4.33pp |
| 2017-12-31 | 98.91% | Skr357.33 Million | Skr361.28 Million | +15.40pp |
| 2016-12-31 | 83.50% | Skr19.11 Million | Skr22.89 Million | -- |